// App-Quantinova.ai

: Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation

Researchers

Presenter

  • Michael Fradley

Principal Investigators

  • Marie-Helene Lafeuille

  • Bruno Emond

  • Samuel Crawford

  • Naijun Chen

  • Raisa Volodarsky

  • Jacqueline Nielsen

  • Bhavini Patel Srivastava

Medical Centers

  • Hospital of the University of Pennsylvania, Perelman School of Medicine, Thalheimer Center for Cardio-Oncology, Abramson Cancer Center and Division of Cardiology, Philadelphia, PA

Locations

  • United States

  • Canada

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Arrhythmia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved